https://invectys.17pixel.com/company/scientific-board/2015-06-23T00:09:44+02:00https://invectys.17pixel.com/in-one/a-global-plateform-for-immunotherapy/2026-01-21T11:57:44+01:00https://invectys.17pixel.com/technology/immune-checkpoint-inhibitor/2015-06-23T00:14:24+02:00https://invectys.17pixel.com/products-and-pipeline/our-pipeline/2015-06-23T00:15:02+02:00https://invectys.17pixel.com/products-and-pipeline/a-vaccine-consisting-of-a-pool-cd4-peptides-of-telomerase/2015-06-23T00:16:50+02:00https://invectys.17pixel.com/slider-en/an-antibody-targeting-a-negative-immune-check-point/2026-01-21T11:59:48+01:00https://invectys.17pixel.com/in-one/about-invectys/2026-01-21T11:58:04+01:00https://invectys.17pixel.com/company/management/2015-06-23T00:09:13+02:00https://invectys.17pixel.com/news/invectys-publications/2015-08-05T11:30:45+02:00https://invectys.17pixel.com/news/invectys-initiates-phase-i-clinical-trial-evaluating-invac-1-therapeutic-vaccine-for-cancer-patients/2015-08-05T13:29:11+02:00https://invectys.17pixel.com/company/invectys-achievements/2015-10-19T10:45:38+02:00https://invectys.17pixel.com/company/mission-and-vision-2/2026-01-21T11:59:17+01:00https://invectys.17pixel.com/news/telomerase-2/2015-11-16T20:07:39+01:00https://invectys.17pixel.com/technology/cancer-unmet-needs/2015-11-18T17:30:58+01:00https://invectys.17pixel.com/news/invectys-receives-ansm-approval-to-start-clinical-trial-for-invac-1-its-leading-anticancer-immunotherapy/2015-11-19T07:17:26+01:00https://invectys.17pixel.com/news/invectys-initiates-phase-i-clinical-trial-evaluating-invac-1-therapeutic-vaccine-for-cancer-patients-2/2015-11-19T07:28:52+01:00https://invectys.17pixel.com/news/invectys-raises-1-7-million-euros-more-to-finance-the-clinical-development-of-its-therapeutic-cancer-vaccine/2015-11-19T08:29:42+01:00https://invectys.17pixel.com/news/%ef%bb%bfinvectys-starts-the-third-dose-level-of-its-phase-i-clinical-trial-evaluating-invac-1-an-innovative-anti-cancer-therapeutic-vaccine/2015-11-19T08:37:57+01:00https://invectys.17pixel.com/news/invectys-raises-a-further-7-million-euros-to-accelerate-clinical-development-of-its-therapeutic-cancer-vaccine/2016-01-27T21:43:40+01:00https://invectys.17pixel.com/news/new-success-for-the-therapeutic-vaccine-invac-1-for-patients-with-cancer/2016-04-01T18:43:02+02:00https://invectys.17pixel.com/news/invectys-renforce-sa-propriete-intellectuelle-dans-un-nouveau-domaine-de-limmunotherapie-anticancereuse/2026-01-21T11:56:10+01:00